CORONA Remedies Limited took a significant leap in women’s healthcare, announcing on June 30, 2026, the commercialisation of its state-of-the-art EU-GMP approved Women’s Hormone manufacturing facility in Bhayla, Ahmedabad. This strategic move underscores the company’s commitment to addressing the rapidly growing global demand for specialized women’s health solutions.
The new facility stands as India’s most advanced dedicated hormone manufacturing plant. This is a critical development, given the complex nature of producing high-potency hormonal medicines and the increasing global focus on hormonal disorders, fertility, and menopause management. CORONA’s investment places it at the forefront of this evolving pharmaceutical landscape.
Key Facility Highlights:
- **Capacity Boost:** Spanning 1.0 lakh sq. ft., the facility boasts an annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels. This is projected to increase CORONA’s in-house hormone manufacturing capacity by nearly 20%.
- **Advanced Manufacturing:** Designed as a purpose-built ecosystem, it ensures complete operational segregation, precision environmental controls, and sophisticated containment for potent APIs. It supports diverse dosage forms including tablets, soft gel capsules, ointments, and gels.
- **Technological Edge:** Incorporating next-generation features like fully integrated closed-loop systems, 21 CFR-compliant equipment, Quality by Design (QbD) principles, and real-time process monitoring, the plant guarantees superior consistency and product quality.
Nirav K. Mehta, Founder, Managing Director & CEO, affirmed: “This dedicated hormone facility strengthens India’s pharmaceutical ecosystem and ensures women have access to safe, reliable, and high-quality hormone therapies.” This strategic investment solidifies CORONA Remedies’ position as a key player in specialized pharmaceutical solutions, poised for future growth.